Entrada Therapeutics Files 8-K on Security Holder Vote
Ticker: TRDA · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1689375
| Field | Detail |
|---|---|
| Company | Entrada Therapeutics, Inc. (TRDA) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Entrada Therapeutics is holding a shareholder vote; details to follow.
AI Summary
Entrada Therapeutics, Inc. filed an 8-K on June 11, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any financial transactions.
Why It Matters
This filing indicates that Entrada Therapeutics is seeking shareholder approval for certain corporate actions, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant corporate events that would immediately impact risk.
Key Players & Entities
- Entrada Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-40969 (company_id) — SEC File Number
- 81-3983399 (company_id) — I.R.S. Employer Identification No.
- Boston, MA (location) — Principal Executive Offices
- ( 857 ) 520-9158 (phone_number) — Registrant's telephone number
FAQ
What specific matters are being submitted for a vote by Entrada Therapeutics' security holders?
The filing states that matters are being submitted to a vote of security holders, but the specific details of these matters are not provided in this initial 8-K filing.
When was this 8-K filing submitted?
The 8-K filing was submitted on June 11, 2025.
What is the principal executive office address for Entrada Therapeutics?
The principal executive office is located at One Design Center Place, Suite 17-500, Boston, MA 02210.
What is the SEC file number for Entrada Therapeutics?
The SEC file number for Entrada Therapeutics is 001-40969.
Does this filing disclose any financial results or significant business updates?
No, this 8-K filing is specifically for reporting the submission of matters to a vote of security holders and does not contain financial results or other business updates.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Entrada Therapeutics, Inc. (TRDA).